Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057534-05
Application #
2098265
Study Section
Pathology B Study Section (PTHB)
Project Start
1992-08-01
Project End
2000-05-31
Budget Start
1996-06-01
Budget End
2000-05-31
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lafky, Jacqueline M; Wilken, Jason A; Baron, Andre T et al. (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232-65
Baron, A T; Lafky, J M; Boardman, C H et al. (1999) Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 8:129-37
Baron, A T; Lafky, J M; Connolly, D C et al. (1998) A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J Immunol Methods 219:23-43
Lee, H; Maihle, N J (1998) Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues. Oncogene 16:3243-52
Baron, A T; Huntley, B K; Lafky, J M et al. (1997) Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain. Hybridoma 16:259-71
Reiter, J L; Maihle, N J (1996) A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res 24:4050-6
Hartmann, L C; Podratz, K C; Keeney, G L et al. (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-9
Jenkins, R B; Bartelt Jr, D; Stalboerger, P et al. (1993) Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 71:76-86